The largest drugmaker within Britain, GlaxoSmithKline, has been hit with the latest in a serious of multinational controversies regarding so-called pay-for-delay deals, used when drugmakers pay the producers of generic drugs to keep their products, often less expensive than brand-names, off the shelves. GSK had reportedly defended its business practices and denied any wrongdoing, but the Office of Fair Trading has accused the company of abusing its market dominance by paying the makers of the generic form of antidepressant Seroxat to delay the sale of their version of the drug. According to the OFT, GSK is accused of colluding with Alpharma, Gerics and Norton Healthcare over the supply of the drug about 10 years ago. The supply agreements were reportedly terminated in 2004. Similar investigations have been initiated within the US and Europe.
Full Content: Euronews
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Fires Two Democratic FTC Members, Raising Questions Over Regulatory Independence
Mar 19, 2025 by
CPI
Spain’s BBVA Remains Optimistic About Hostile Takeover of Sabadell
Mar 18, 2025 by
CPI
BlackRock, Vanguard and State Street Seek Dismissal of Texas Antitrust Lawsuit
Mar 18, 2025 by
CPI
EU to Boost Metal Sectors with Energy Relief and Safeguards
Mar 18, 2025 by
CPI
Players’ Association Sues Tennis Governing Bodies Over Alleged Antitrust Violations
Mar 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li